MannKind Says 6-Month Results of Phase 3 Study for Inhaled Insulin Afrezza Meet Primary Endpoint

MT Newswires21:00

MannKind Announced Six-month Results From Its Phase 3 Inhale-1 Study Of Afrezza (Insulin Human) Inhalation Powder In Children And Adolescents (Aged 4-17 Years). MannKind Expects To Submit A Request For Supplemental New Drug Application Meeting With...

Benzinga19:07

Express News | MannKind Corp: Primary Endpoint Was Non-Inferior Change in Hba1C Levels After 26 Weeks

Breakings19:06

Express News | MannKind Corp: Expects to Ship Product for Cipla Ltd. by End of 2025

BreakingsDec 11 19:05

CDSCO Approves Afrezza (Insulin Human) Inhalation Powder in India

GlobeNewswireDec 11 19:00

MannKind Corporation's (NASDAQ:MNKD) Institutional Investors Lost 3.9% Last Week but Have Benefitted From Longer-term Gains

Simply Wall StNov 28 21:44